

Haematologica  
HAEMATOL/2018/208272  
Version 3

Once-weekly versus twice-weekly carfilzomib in patients with newly  
diagnosed multiple myeloma: a pooled analysis of two phase 1/2  
studies

Sara Brinthen, Roberto Mina, Maria Teresa Petrucci, Gianluca Gaidano, Stelvio Ballanti, Pellegrino Musto, Massimo Offidani, Stefano Spada, Giulia Benevolo, Elena Ponticelli, Piero Galieni, Michele Cavo, Tommaso Caravita di Toritto, Francesco Di Raimondo, Vittorio Montefusco, Antonio Palumbo, Mario Boccadoro, and Alessandra Larocca

Disclosures: SB has received honoraria from Bristol-Myers Squibb, Celgene, Amgen, and Janssen; has served on the advisory boards for Amgen, Janssen, Karyopharm, and Celgene; has undertaken consultancy for Takeda and Janssen. MTP has received honoraria from Celgene, Janssen-Cilag, Bristol-Myers Squibb, Takeda, and Amgen; has served on the advisory boards for Celgene, Janssen-Cilag, Bristol-Myers Squibb, Takeda, and Amgen. GG has served on the advisory boards for Janssen and AbbVie; has served on the speakers' bureaus for Janssen, Gilead and AbbVie. PM has received personal fees from Amgen, Novartis, BMS, Celgene, Janssen and Takeda. MO has received honoraria from and has served on the advisory board for Amgen. MC has received grants from Janssen and Celgene; has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, and Takeda. TCDT has served on the advisory boards for Celgene, Johnson & Johnson, Amgen, Takeda, and BMS; has received research funding from Celgene; has received support (travel and accommodation costs) from Amgen, Celgene, and Johnson & Johnson. FDR has received grants from Janssen, Celgene and Bristol-Myers Squibb. VM has received consultancy fees from Amgen. AP is currently a Takeda International employee and owns stocks from Takeda International. MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, AbbVie, and Bristol-Myers Squibb; has received research funding from Celgene, Janssen, Amgen, Bristol-Myers Squibb, Mundipharma, Novartis, and Sanofi. AL has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, and Janssen; has served on the advisory boards for Bristol-Myers Squibb, Celgene, Janssen, and Takeda. The remaining authors declare no competing financial interests.

Contributions: Substantial contributions to the conception or design: SB, RM, SS, and MB. Acquisition, analysis, or interpretation of data: all authors. First draft: RM and SB. Statistical analysis: SS. Supervision: SB, MB, and AL. Critical revision for important intellectual content: all authors. Final approval of the version to be published: all authors. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: all authors.